Shanks, Hayley R. C. http://orcid.org/0000-0003-4502-7170
Chen, Kewei http://orcid.org/0000-0001-8497-3069
Reiman, Eric M. http://orcid.org/0000-0002-0705-3696
Blennow, Kaj http://orcid.org/0000-0002-1890-4193
Cummings, Jeffrey L.
Massa, Stephen M. http://orcid.org/0000-0003-0474-4886
Longo, Frank M. http://orcid.org/0000-0002-9514-7325
Börjesson-Hanson, Anne
Windisch, Manfred http://orcid.org/0000-0003-1490-7933
Schmitz, Taylor W. http://orcid.org/0000-0003-0585-7524
Article History
Received: 1 November 2023
Accepted: 4 April 2024
First Online: 17 May 2024
Competing interests
: K.C. is a consultant to ADM Diagnostics. E.M.R. is a compensated scientific advisor to Alzheon, Aural Analytics, Cognition Therapeutics, Denali, Enigma, Retromer Therapeutics and Vaxxinity and a cofounder and advisor of ALZPath. K.B. has provided consultation to Abbvie, AC Immune, AriBio, ALZpath, BioArctic, Biogen, Eisai, Lilly, Ono Pharma, Prothena, Roche Diagnostics and Siemens Healthineers. K.B. has participated in a data safety monitoring board or advisory board for Julius Clinical and Novartis. K.B. has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics. K.B. is a cofounder of and has stock in Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. J.L.C. has provided consultation to Acadia, Actinogen, Acumen, AlphaCognition, Aprinoia, Artery, Biogen, Biohaven, BioXcel, Bristol-Myers Squib, Cassava, Cerecin, Eisai, GAP Foundation, Janssen, Karuna, Lighthouse, Lilly, Lundbeck, EQT (formerly LSP), Merck, NervGen, New Amsterdam, Novo Nordisk, Oligomerix, Optoceutics, Ono, Otsuka, Oxford Brain Diagnostics, PharmatrophiX, Prothena, ReMYND, Roche, Sage Therapeutics, Scottish Brain Science, Signant Health, Simcere, sinaptica, Suven, TrueBinding, Vaxxinity and Wren pharmaceutical, assessment and investment companies. F.M.L. and S.M.M. are listed as inventors on patents related to LM11A-31 that are assigned to the University of North Carolina, University of California, San Francisco and the Department of Veterans Affairs. They are also entitled to royalties distributed by UC and the VA per their standard agreements. F.M.L. is a principal of and has financial interest in PharmatrophiX, a company focused on the development of small-molecule ligands for neurotrophin receptors, with licensing of several related patents. M.W. is the vice president for research and development of NeuroScios. The other authors declare no competing interests.